360 related articles for article (PubMed ID: 30256692)
1. Omalizumab therapy in a patient with cronic spontaneous urticaria, ulcerative colitis, hypereosinophilia and prurigo Besnier: a case report.
Grieco T; Chello C; Faina V; Gomes VV; Alei L; Sernicola A; Panasiti V; Calvieri S
J Dermatolog Treat; 2018; 29(sup3):10-13. PubMed ID: 30256692
[TBL] [Abstract][Full Text] [Related]
2. Combining Omalizumab with Another Biotherapy.
Fougerousse AC; Becherel PA; Pallure V; Boyé T; Reguiai Z; Gabison G; Barthelemy H; Badaoui A; Mahé E; Livideanu CB;
Acta Derm Venereol; 2019 Apr; 99(4):448-449. PubMed ID: 30723874
[No Abstract] [Full Text] [Related]
3. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
[TBL] [Abstract][Full Text] [Related]
4. Concurrent use of omalizumab and dupilumab in a 47-year-old woman with chronic spontaneous urticaria and atopic dermatitis.
Holm JG; Sørensen JA; Thomsen SF
Int J Dermatol; 2022 May; 61(5):e173-e174. PubMed ID: 34813086
[No Abstract] [Full Text] [Related]
5. Use of omalizumab in the treatment of chronic urticaria.
Cordeiro Moreira AS; Rosmaninho Lopes de Soares E Silva MI; Pereira Guilherme MA; da Silva Ferreira JA; Fonseca Moreira da Silva JP
Eur Ann Allergy Clin Immunol; 2016 Nov; 48(6):242-246. PubMed ID: 27852430
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of omalizumab in chronic spontaneous urticaria assessed with patient-reported outcomes: a prospective study.
Ghazanfar MN; Holm JG; Thomsen SF
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1761-1767. PubMed ID: 29729103
[TBL] [Abstract][Full Text] [Related]
7. A case of chronic prurigo successfully treated with omalizumab.
Ugajin T; Inazawa M; Inui K; Namiki T; Yokozeki H
Eur J Dermatol; 2018 Oct; 28(5):691-692. PubMed ID: 29952307
[No Abstract] [Full Text] [Related]
8. Omalizumab for treating chronic spontaneous urticaria: an expert review on efficacy and safety.
Giménez-Arnau AM
Expert Opin Biol Ther; 2017 Mar; 17(3):375-385. PubMed ID: 28125304
[TBL] [Abstract][Full Text] [Related]
9. Basophil FcεRI Expression in Chronic Spontaneous Urticaria: A Potential Immunological Predictor of Response to Omalizumab Therapy.
Deza G; Bertolín-Colilla M; Pujol RM; Curto-Barredo L; Soto D; García M; Hernández P; Gimeno R; Giménez-Arnau AM
Acta Derm Venereol; 2017 Jun; 97(6):698-704. PubMed ID: 28303277
[TBL] [Abstract][Full Text] [Related]
10. Omalizumab for refractory chronic spontaneous urticaria during concurrent immunomodulatory therapy for multiple sclerosis.
Syrigos N; Grapsa D; Syrigou E
Eur Ann Allergy Clin Immunol; 2017 Nov; 49(6):286-287. PubMed ID: 29249139
[TBL] [Abstract][Full Text] [Related]
11. Omalizumab in Chronic Urticaria: An Italian Survey.
Damiani G; Diani M; Conic RRZ; Colli L; Ferrucci S; Martina E; Offidani AM; Pigatto PDM
Int Arch Allergy Immunol; 2019; 178(1):45-49. PubMed ID: 30396176
[TBL] [Abstract][Full Text] [Related]
12. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria.
Kaplan A; Ferrer M; Bernstein JA; Antonova E; Trzaskoma B; Raimundo K; Rosén K; Omachi TA; Khalil S; Zazzali JL
J Allergy Clin Immunol; 2016 Feb; 137(2):474-81. PubMed ID: 26483177
[TBL] [Abstract][Full Text] [Related]
13. Omalizumab is effective in patients with chronic spontaneous urticaria plus multiple chronic inducible urticaria.
Skander D; Allenova A; Maurer M; Kolkhir P
Eur Ann Allergy Clin Immunol; 2021 Mar; 53(2):91-93. PubMed ID: 32496030
[No Abstract] [Full Text] [Related]
14. Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria.
Giménez-Arnau AM; Toubi E; Marsland AM; Maurer M
J Eur Acad Dermatol Venereol; 2016 Jul; 30 Suppl 5():25-32. PubMed ID: 27286500
[TBL] [Abstract][Full Text] [Related]
15. Serial D-dimer plasma levels in a patient with chronic spontaneous urticaria developing resistance to omalizumab.
Asero R
Clin Exp Dermatol; 2017 Aug; 42(6):667-669. PubMed ID: 28691309
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab: what benefits should we expect?
Giménez-Arnau A; Velasco M; Armario Hita JC; Labrador-Horrillo M; Silvestre Salvador JF
Eur J Dermatol; 2016 Aug; 26(4):340-4. PubMed ID: 27210073
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with omalizumab and etanercept in a patient with chronic spontaneous urticaria and rheumatoid arthritis.
Ghazanfar MN; Thomsen SF
J Dermatolog Treat; 2019 Jun; 30(4):387-388. PubMed ID: 30132352
[TBL] [Abstract][Full Text] [Related]
18. Omalizumab in chronic spontaneous and inducible urticaria: a 9 year retrospective study in Portugal.
Marcelino J; Costa AC; Mendes A; Alonso E; Cabral Duarte F; Pedro E; Pereira-Barbosa M
Eur Ann Allergy Clin Immunol; 2018 Jul; 50(4):169-176. PubMed ID: 29479938
[No Abstract] [Full Text] [Related]
19. Omalizumab use during pregnancy for chronic spontaneous urticaria (CSU): report of two cases.
González-Medina M; Curto-Barredo L; Labrador-Horrillo M; Giménez-Arnau A
J Eur Acad Dermatol Venereol; 2017 May; 31(5):e245-e246. PubMed ID: 27868240
[No Abstract] [Full Text] [Related]
20. Efficacy of omalizumab 150 mg/month as a maintenance dose in patients with severe chronic spontaneous urticaria showing a prompt and complete response to the drug.
Asero R
Allergy; 2018 Nov; 73(11):2242-2244. PubMed ID: 29989179
[No Abstract] [Full Text] [Related]
[Next] [New Search]
